India: Recent Orders Of CCI Against Anti-Competitive Practices In The Pharmaceutical Industry

The Indian pharmaceutical industry is emerging as one of the most prospective markets in the global strata in terms of its potential and factors such as lower labor cost, resource availability etc. which is bringing it to the limelight of various international giant players all across the globe for venturing into business or investments in the Indian domestic market. However, the growth emergence of the market is also leading to the emergence of certain practices in the market affecting the pace of growth of the market which may in certain point, led to a descending dive as it discourages the enthusiasm of those international giants to venture into the complicacies of the Indian market.

Recently, the industry has witnessed of practices by the players of the market, which acts as disrupting factors against "the positive competition" in the market which is an essential ingredient of every market so as it to proceed towards more innovations and developments as an outcome of such positive competition.

In the study on "Option for using Competition Law/ policy tools in dealing with anti-competitive practices in the Pharmaceuticals Industry in the Health delivery System" prepared for WHO and the Ministry of Health and Family Welfare in 20061, it is quoted that anticompetitive practices in the pharmaceuticals sector and the health delivery system in India, includes, amongst others, price fixing, abuse of dominance, collusive agreements and tied selling.

In India, the Competition Commission of India ('CCI') is the authority which has established under the Competition Act, 2002 (Act) to eliminate practices having adverse effect on competition, promote and sustain competition, protect the interests of consumers and ensure freedom of trade carried on by other participants, in markets in India. It covers within its ambit all categories of 'markets' in India including the pharmaceuticals sector as well. Moreover, the Act is extra-territorial and assumes jurisdiction over acts even outside India that may affect a market within India.

This article endeavors to throw light on the recent regulatory steps of CCI towards prevention of anticompetitive practices in the pharmaceutical industry and discusses some of its recent orders to regulate anti-competitive practices in the pharmaceutical market.

Implementation of the regulatory mechanism by the CCI

In a recent judgment Bengal Chemist and Druggist Association,2the CCI Imposes penalty of Rs. 18.38 crores on Bengal Chemist and Druggist Association (BCDA).3

Facts: BCDA, an association of wholesalers and retail sellers of drugs and affiliated to All India Organization of Chemist and Druggist was engaged in directly or indirectly determining the sale price of drugs and controlling the supply of drugs in a concerted manner and in issuing anti-competitive circulars directing the retailers not to give any discount to the consumers. The CCI after considering the entire material directed the Director General (DG) to cause an investigation into the matter and to submit a report.4

Investigation report by Direct or General

The Director General, in light of the investigation conducted, opined that the BCDA directed the retailers to sell the drugs only at MRP determined by it on account of agreement entered into amongst the members of the BCDA and that no discounts be offered by the retailers, it clearly implies that, then such a trade practice causes or is likely to cause an appreciable adverse effect on competition, especially when almost all the retailers and wholesalers are members of BCDA. The DG concluded that the above said conduct has resulted or is likely to result in controlling and or limiting supply of medicines and the market of provision of drugs, which contravene the provisions of Section 3(3)(b) of the Act.

CCI's finding:

The CCI firstly, dealt with the question as to whether BCDA is covered under the category of 'entities' under Section 3(3) read with Section 2(h) of the Act and whether the alleged practices of BCDA falls under "practice carried on" or decision taken by "an association of enterprises" under Section 3(3) of the Act. The CCI concluded that BCDA, being an association of its constituent enterprises, is taking decisions relating to distribution and supply of pharma products on behalf of the members who are engaged in similar or identical trade of goods and that such practices carried on, or decisions taken, by BCDA as an association of enterprises are covered within the scope of Section 3(3) of the Act.

Further, the CCI holds that the attempt of BCDA to justify sale of drugs only on MRP on the basis that the margins have been fixed under the DPCO and accepted in the market is untenable as the issue is not the reasonability or the quantum of trade margins but the concerted action to fix uniform trade margin by an agreement amongst the members of the trade association. The CCI found the activities of the BCDA in conflict with the objects of the competition law as they cause restraint of trade, stifle competition and harm the consumers.


The CCI directed the BCDA and its office bearers & executive committee members to seize and desist from indulging in anticompetitive practices found to be anticompetitive in terms of the provisions of Section 3 of the Act. The BCDA has been further directed to file an undertaking within 30 days that the CCI's directions have been complied with. The amount of penalty imposed was directed to be deposited within 60 of the receipt of the order.

In another judgment, M/s Arora Medical Hall, Ferozepur v. Chemists &Druggists Association, Ferozepur (CDAF),5 the CCI ordered another judgment imposing a penalty of Rs.55.42 lakhs on Ferozepur Chemists and Druggists Association.6

Facts: M/s Arora Medical Hall, Ferozepur informed the CCI that the CDAF made a mandatory rule in 2010 that any chemist/ druggist who wishes to take distributorship for medicines of a company in Ferozepur city to get a NOC and Letter of Credit (LOC) from CDAF by making a payment of Rs. 2100/- per company. The informant alleged that when it objected to the said rule, it was expelled from the primary membership of CDAF and passed a resolution to boycott the informant directing its members to stop purchasing goods from the informant and directed all the wholesalers to stop dealings with the retailers who continued to purchase goods from the informant and thereby, alleged to have violated the provisions of sections 3 and 4 of the Competition Act.

The Director General reported that CDAF's practice of necessarily requiring NOC to be taken from it prior to appointment of a new/ additional stockist in Ferozepur and indulging in the practice of non-grant of NOC to non-members is foreclosing the market for such nonmember which has the effect of limiting and controlling the supply of drugs and medicines in Ferozepur.

Order of CCI

The CCI directed CDAF to cease and desist from indulging in such anti-competitive practices which have been found to be anti-competitive in terms of the provisions of section 3(3)(b) read with Section 3(1) of the Act and imposed penalty accordingly.

On 3 February 2014, Press Information Bureau, Government of India, Ministry of Corporate Affairs vide press release informed that CCI has found the following practices of All India level, State level, District level associations of chemists, druggists, stockists, wholesellers and manufacturers as anti-competitive:

  1. Issuance of No Objection Certificate or letter of consent by such associations for opening chemist shop/being appointed stockists/ distributor/whole-seller.
  2. Compulsory payment of PIS charges by pharmaceutical firms/manufacturers to associations for release of new drug/new formulation.
  3. Fixation of trade margins at different levels of sale of drugs/medicines.
  4. Issuance of instructions to chemists/ druggists/shops/stockists/whole-sellers/ manufacturers restricting discounts on sale of drugs in retail or wholesale.
  5. Issuance of boycott calls by the associations to their members against any enterprise for not following the instructions of associations.

It is also mentioned in the press release dated 3 February 2014 that penalties have been imposed by the CCI on such trade associations of chemists and druggists for violation of provisions of Competition Act. The CCI had issued cease & desist order against the associations directing them not to indulge in anticompetitive practices and the associations have filed undertakings that they would not indulge in such illegal practices.


It is noteworthy that the CCI's stringency towards the objective of eliminating and regulating against the malpractices from the pharmaceutical market is also evidently clear from the press release of 3 February 2014 that in case any drug manufacturer or concerned party is victim of any anti- competitive practice described above, it may notify the CCI who shall take appropriate action as required, usually in the nature of criminal proceedings against the guilty associations and its office-bearers, and imposition of heavy monetary penalty.

To conclude with, such initiatives by CCI clearly indicate that it intends to bring into its stringent control on the mechanism of the pharmaceutical industry so as to regulate it against all the anti-competitive practices prevailing in the market thereby deterring those players of the market who indulged into such practices for their gain.

It further expected to bring a positive impact on the distribution of medicines in India as well as prices charged to the customers, thus with it, the hope that the Indian pharmaceutical market will move towards being more systematic and organized.



2. Suo moto Case No. 02 of 2012 and Ref. Case No. 01 of 2013, Competition Commission of India order, available at http://

3. Press Information Bureau, Ministry of Corporate Affairs, Government of India notification available at newsite/PrintRelease.aspx?relid=104597.

4. This has been done vide a common order in Suo moto Case No. 02 of 2012 and Reference Case No. 01 of 2013 filed by Dr. Chintamoni Ghosh, Director, Directorate of Drugs, West Bengal.

5. Case No. 60 of 2012, Competition Commission of India order, available at .

6. Press Information Bureau, Ministry of Corporate Affairs, Government of India notification available at newsite/PrintRelease.aspx?relid=103171

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions